Does_VBZ
thyroidectomy_NN
,_,
radioactive_JJ
iodine_NN
therapy_NN
,_,
or_CC
antithyroid_JJ
drug_NN
treatment_NN
alter_VB
reactivity_NN
of_IN
patients_NNS
'_POS
T_NN
cells_NNS
to_TO
epitopes_NNS
of_IN
thyrotropin_NN
receptor_NN
in_IN
autoimmune_JJ
thyroid_NN
diseases_NNS
?_.

The_DT
effect_NN
of_IN
treatment_NN
on_IN
thyroid_NN
antibody_NN
production_NN
and_CC
T_NN
cell_NN
reactivity_NN
to_TO
thyroid_NN
antigens_NNS
was_VBD
studied_VBN
in_IN
15_CD
patients_NNS
with_IN
Graves_NN
'_POS
disease_NN
-LRB-_-LRB-
GD_NN
-RRB-_-RRB-
before_IN
and_CC
after_IN
thyroidectomy_NN
,_,
19_CD
patients_NNS
with_IN
GD_NN
before_IN
and_CC
after_IN
radioactive_JJ
iodine_NN
-LRB-_-LRB-
RAI_NN
-RRB-_-RRB-
therapy_NN
,_,
and_CC
9_CD
patients_NNS
maintained_VBD
euthyroid_JJ
on_IN
antithyroid_JJ
drugs_NNS
-LRB-_-LRB-
ATD_NN
-RRB-_-RRB-
._.

Twenty_CD
subjects_NNS
matched_VBN
for_IN
age_NN
and_CC
sex_NN
without_IN
known_JJ
thyroid_NN
disease_NN
served_VBD
as_IN
controls_NNS
._.

In_IN
GD_NN
patients_NNS
,_,
the_DT
responses_NNS
of_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMC_NN
-RRB-_-RRB-
and_CC
TSH_NN
receptor_NN
-LRB-_-LRB-
TSHR_NN
-RRB-_-RRB-
-_:
specific_JJ
T_NN
cell_NN
lines_NNS
to_TO
recombinant_JJ
human_JJ
TSHR_NN
extracellular_JJ
domain_NN
,_,
thyroglobulin_NN
,_,
and_CC
TSHR_NN
peptides_NNS
were_VBD
examined_VBN
on_IN
the_DT
day_NN
of_IN
surgery_NN
or_CC
RAI_NN
therapy_NN
-LRB-_-LRB-
day_NN
0_CD
-RRB-_-RRB-
and_CC
also_RB
6-8_CD
weeks_NNS
and_CC
3-6_CD
months_NNS
thereafter_RB
._.

Reactivity_NN
to_TO
TSHR_NN
peptides_NNS
before_IN
surgery_NN
was_VBD
heterogeneous_JJ
and_CC
spanned_VBD
the_DT
entire_JJ
extracellular_JJ
domain_NN
._.

Six_CD
to_TO
8_CD
weeks_NNS
after_IN
subtotal_JJ
thyroidectomy_NN
,_,
the_DT
number_NN
of_IN
patients_NNS
'_POS
PBMC_NNS
responding_VBZ
to_TO
any_DT
peptide_NN
and_CC
the_DT
average_JJ
number_NN
of_IN
recognized_VBN
peptides_NNS
decreased_VBN
._.

A_DT
further_JJ
decrease_NN
in_IN
the_DT
T_NN
cell_NN
reactivity_NN
to_TO
TSHR_NN
peptides_NNS
was_VBD
observed_VBN
3-6_CD
months_NNS
after_IN
surgery_NN
._.

The_DT
responses_NNS
of_IN
PBMC_NN
from_IN
Graves_NN
'_POS
patients_NNS
before_IN
RAI_NN
therapy_NN
were_VBD
less_JJR
than_IN
those_DT
in_IN
the_DT
presurgical_JJ
group_NN
._.

Six_CD
to_TO
8_CD
weeks_NNS
after_IN
RAI_NN
therapy_NN
,_,
the_DT
number_NN
of_IN
patients_NNS
responding_VBZ
to_TO
any_DT
peptide_NN
and_CC
the_DT
average_JJ
number_NN
of_IN
recognized_VBN
peptides_NNS
increased_VBN
._.

Three_CD
to_TO
6_CD
months_NNS
after_IN
RAI_NN
,_,
T_NN
cell_NN
responses_NNS
to_TO
TSHR_NN
peptides_NNS
were_VBD
less_JJR
than_IN
those_DT
6-8_CD
weeks_NNS
after_IN
RAI_NN
therapy_NN
,_,
but_CC
still_RB
higher_JJR
than_IN
the_DT
values_NNS
on_IN
day_NN
0_CD
._.

Responses_NNS
of_IN
PBMC_NN
from_IN
patients_NNS
with_IN
GD_NN
,_,
maintained_VBN
euthyroid_JJ
on_IN
ATD_NN
,_,
were_VBD
lower_JJR
than_IN
those_DT
before_IN
surgery_NN
or_CC
RAI_NN
therapy_NN
._.

The_DT
reactivity_NN
of_IN
T_NN
cell_NN
lines_NNS
in_IN
different_JJ
groups_NNS
reflected_VBD
a_DT
pattern_NN
similar_JJ
to_TO
PBMC_NN
after_IN
treatment_NN
._.

TSHR_NN
antibody_NN
and_CC
microsomal_JJ
antibody_NN
levels_NNS
decreased_VBD
after_IN
surgery_NN
,_,
but_CC
increased_VBD
after_IN
RAI_NN
therapy_NN
._.

The_DT
difference_NN
in_IN
the_DT
number_NN
of_IN
recognized_VBN
peptides_NNS
by_IN
patients_NNS
'_POS
PBMC_NNS
before_IN
RAI_NN
and_CC
surgery_NN
may_MD
reflect_VB
the_DT
effect_NN
of_IN
long_JJ
term_NN
therapy_NN
with_IN
ATD_NN
in_IN
the_DT
patients_NNS
before_IN
RAI_NN
vs._CC
the_DT
shorter_JJR
period_NN
in_IN
patients_NNS
before_IN
surgery_NN
._.

The_DT
decreased_VBN
T_NN
cell_NN
reactivity_NN
to_TO
thyroid_NN
antigens_NNS
after_IN
thyroidectomy_NN
could_MD
be_VB
the_DT
result_NN
of_IN
removal_NN
of_IN
a_DT
major_JJ
part_NN
of_IN
the_DT
thyroid_NN
gland_NN
or_CC
redistribution_NN
of_IN
suppressor-inducer_JJ
T_NN
cells_NNS
._.

The_DT
increased_VBN
T_NN
cell_NN
response_NN
after_IN
RAI_NN
therapy_NN
is_VBZ
probably_RB
epitope_NN
specific_JJ
,_,
rather_RB
than_IN
a_DT
response_NN
to_TO
the_DT
whole_JJ
TSHR_NN
molecule_NN
._.

Synchronous_JJ
recognition_NN
of_IN
peptides_NNS
158-176_CD
and_CC
248-263_CD
is_VBZ
important_JJ
for_IN
the_DT
development_NN
of_IN
GD_NN
,_,
and_CC
the_DT
loss_NN
of_IN
recognition_NN
of_IN
one_CD
of_IN
these_DT
epitopes_NNS
may_MD
be_VB
an_DT
early_JJ
sign_NN
of_IN
immune_JJ
remission_NN
and_CC
a_DT
predictor_NN
of_IN
euthyroidism_NN
._.

